RT @tangming2005: 6/ 2021 Nature Med [A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer](h…
RT @tangming2005: 6/ 2021 Nature Med [A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer](h…
6/ 2021 Nature Med [A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer](https://t.co/ecOhHjTTmJ)
EW: Motivated by scRNA-seq and scTCR-seq study of pembrolizumab anti-PD1 treatment in breast cancer #JSM2023 https://t.co/0vD9s2ko5e
@LambrechtsDlab The focus is on identifying the immune response towards PD1 treatments in breast cancer. Results published here: https://t.co/0ai7gviCkH #ATCR23
RT @NatureMedicine: Transcriptomic and proteomic profiling of #breastcancer biopsies identifies baseline features of the tumor immune micro…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: Resurrecting this thread and see if you can add more. #singlecell https://t.co/RrCzpT0UHo
Resurrecting this thread and see if you can add more. #singlecell
RT @NatureMedicine: To raise awareness for #breastcancer awareness month this is a study on the single-cell map of #intratumoral changes du…
RT @NatureMedicine: To raise awareness for #breastcancer awareness month this is a study on the single-cell map of #intratumoral changes du…
RT @NatureMedicine: To raise awareness for #breastcancer awareness month this is a study on the single-cell map of #intratumoral changes du…
RT @NatureMedicine: To raise awareness for #breastcancer awareness month this is a study on the single-cell map of #intratumoral changes du…
RT @NatureMedicine: To raise awareness for #breastcancer awareness month this is a study on the single-cell map of #intratumoral changes du…
RT @NatureMedicine: To raise awareness for #breastcancer awareness month this is a study on the single-cell map of #intratumoral changes du…
RT @NatureMedicine: To raise awareness for #breastcancer awareness month this is a study on the single-cell map of #intratumoral changes du…
RT @NatureMedicine: To raise awareness for #breastcancer awareness month this is a study on the single-cell map of #intratumoral changes du…
To raise awareness for #breastcancer awareness month this is a study on the single-cell map of #intratumoral changes during anti-#PD1 treatment of patients with breast cancer #breastcancerawareness #pinkoctober #NoTimeToWaste https://t.co/pSPnK2dWGC
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
I will share the list later. Any more papers?
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @theHumanBorch: If you have publications on immunotherapy and the data is public, think about contributing to the effort from @tangming2…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @theHumanBorch: If you have publications on immunotherapy and the data is public, think about contributing to the effort from @tangming2…
RT @theHumanBorch: If you have publications on immunotherapy and the data is public, think about contributing to the effort from @tangming2…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
If you have publications on immunotherapy and the data is public, think about contributing to the effort from @tangming2005. Way too many publications in the field have "data available upon request."
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
Transcriptomics of immunotherapy
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
RT @tangming2005: 1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https…
1/ collecting scRNAseq data in the context of immunotherapy. I will share what I know here. welcome to contribute. https://t.co/Hy3u5Hgpo1
Great breast cancer study that highlights powerful Tumor Infiltrating Lympohocyte (TIL) profiling. Using pre-treatment biopsies researchers created TIL profiles and identified molecular signatures associated with aPD-1 treatment efficacy. https://t.co/ja
RT @NatureMedicine: Transcriptomic and proteomic profiling of #breastcancer biopsies identifies baseline features of the tumor immune micro…
Transcriptomic and proteomic profiling of #breastcancer biopsies identifies baseline features of the tumor immune microenvironment associated with T cell clonal expansion following neoadjuvant anti-PD-1 treatment @LambrechtsDlab #BreastCancerAwarenessMonth
RT @IMMUCan: On #BreastCancerAwarenessMonth we are highlighting important strides in #CancerResearch in the fight against #BreastCancer. T…
RT @IMMUCan: On #BreastCancerAwarenessMonth we are highlighting important strides in #CancerResearch in the fight against #BreastCancer. T…
On #BreastCancerAwarenessMonth we are highlighting important strides in #CancerResearch in the fight against #BreastCancer. This week: this @NatureMedicine study📑 shedding light on the varied responses to a checkpoint inhibitor anti-#cancer treatment. 🔗h
RT @carmonation: Exhausted CD8 TILs are good not bad: new ProjecTILs Case Study (https://t.co/40SttGqmUl). A quick re-analysis of scRNA-seq…
RT @NatureMedicine: Transcriptomic and proteomic profiling of #breastcancer biopsies identifies baseline features of the tumor immune micro…
RT @carmonation: Exhausted CD8 TILs are good not bad: new ProjecTILs Case Study (https://t.co/40SttGqmUl). A quick re-analysis of scRNA-seq…
RT @carmonation: Exhausted CD8 TILs are good not bad: new ProjecTILs Case Study (https://t.co/40SttGqmUl). A quick re-analysis of scRNA-seq…
RT @carmonation: Exhausted CD8 TILs are good not bad: new ProjecTILs Case Study (https://t.co/40SttGqmUl). A quick re-analysis of scRNA-seq…
RT @carmonation: Exhausted CD8 TILs are good not bad: new ProjecTILs Case Study (https://t.co/40SttGqmUl). A quick re-analysis of scRNA-seq…
RT @carmonation: Exhausted CD8 TILs are good not bad: new ProjecTILs Case Study (https://t.co/40SttGqmUl). A quick re-analysis of scRNA-seq…
RT @carmonation: Exhausted CD8 TILs are good not bad: new ProjecTILs Case Study (https://t.co/40SttGqmUl). A quick re-analysis of scRNA-seq…
RT @carmonation: Exhausted CD8 TILs are good not bad: new ProjecTILs Case Study (https://t.co/40SttGqmUl). A quick re-analysis of scRNA-seq…
Learning about T cells thru' scRNA-seq data
RT @carmonation: Exhausted CD8 TILs are good not bad: new ProjecTILs Case Study (https://t.co/40SttGqmUl). A quick re-analysis of scRNA-seq…
RT @carmonation: Exhausted CD8 TILs are good not bad: new ProjecTILs Case Study (https://t.co/40SttGqmUl). A quick re-analysis of scRNA-seq…
RT @carmonation: Exhausted CD8 TILs are good not bad: new ProjecTILs Case Study (https://t.co/40SttGqmUl). A quick re-analysis of scRNA-seq…
RT @carmonation: Exhausted CD8 TILs are good not bad: new ProjecTILs Case Study (https://t.co/40SttGqmUl). A quick re-analysis of scRNA-seq…
RT @carmonation: Exhausted CD8 TILs are good not bad: new ProjecTILs Case Study (https://t.co/40SttGqmUl). A quick re-analysis of scRNA-seq…
RT @carmonation: Exhausted CD8 TILs are good not bad: new ProjecTILs Case Study (https://t.co/40SttGqmUl). A quick re-analysis of scRNA-seq…
RT @carmonation: Exhausted CD8 TILs are good not bad: new ProjecTILs Case Study (https://t.co/40SttGqmUl). A quick re-analysis of scRNA-seq…
RT @carmonation: Exhausted CD8 TILs are good not bad: new ProjecTILs Case Study (https://t.co/40SttGqmUl). A quick re-analysis of scRNA-seq…
RT @carmonation: Exhausted CD8 TILs are good not bad: new ProjecTILs Case Study (https://t.co/40SttGqmUl). A quick re-analysis of scRNA-seq…
RT @carmonation: Exhausted CD8 TILs are good not bad: new ProjecTILs Case Study (https://t.co/40SttGqmUl). A quick re-analysis of scRNA-seq…
Exhausted CD8 TILs are good not bad: new ProjecTILs Case Study (https://t.co/40SttGqmUl). A quick re-analysis of scRNA-seq data of breast cancer patients treated with anti-PD-1 therapy by Bassez et al. (https://t.co/g4UyrGjDX5). https://t.co/rfJKGrupPh
RT @manolosesmero: A single-cell map of intratumoral changes during anti-PD1 treatment of patients with #breastcancer #icb @NatureMedicine…
RT @manolosesmero: A single-cell map of intratumoral changes during anti-PD1 treatment of patients with #breastcancer #icb @NatureMedicine…
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with #breastcancer #icb @NatureMedicine https://t.co/vYFKtodoq4
RT @NatureMedicine: Transcriptomic and proteomic profiling of #breastcancer biopsies identifies baseline features of the tumor immune micro…
@VIBLifeSciences
RT @NatureMedicine: Transcriptomic and proteomic profiling of #breastcancer biopsies identifies baseline features of the tumor immune micro…
RT @NatureMedicine: Transcriptomic and proteomic profiling of #breastcancer biopsies identifies baseline features of the tumor immune micro…
RT @NatureMedicine: Transcriptomic and proteomic profiling of #breastcancer biopsies identifies baseline features of the tumor immune micro…
RT @NatureMedicine: Transcriptomic and proteomic profiling of #breastcancer biopsies identifies baseline features of the tumor immune micro…
RT @NatureMedicine: Transcriptomic and proteomic profiling of #breastcancer biopsies identifies baseline features of the tumor immune micro…
RT @NatureMedicine: Transcriptomic and proteomic profiling of #breastcancer biopsies identifies baseline features of the tumor immune micro…